就像大型生物技术公司健赞的首席执行官亨利·特米尔(Henri Termeer)所说，“随着时间的推移，个人化药物的推出，依靠拳头产品的商业模式变得越来越不重要了。”
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”
健赞的董事会正式地拒绝了赛诺菲·安万特敌意收购其公司的消息新鲜出炉，交易观察家们正满腹猜疑。
Fresh off the news that Genzyme's board officially nixed Sanofi-Aventis' hostile bid for the company, deal-watchers are gathering, full of speculation and possibilities.
应用推荐